Skip to content

Fusion Pharmaceuticals Inc.

CIK 0001805890

← back to feed
Revenue (TTM)
$2.23M
+41.5% YoY Q1 Apr 2024
Net Income (TTM)
−$100.39M
−8.3% YoY Q1 Apr 2024
EPS Diluted (TTM)
−$1.48
+27.5% YoY Q1 Apr 2024
Gross Margin
—
Q1 Apr 2024
Operating Margin
-4,781.4%
Q1 Apr 2024
Net Margin
-4,493.6%
Q1 Apr 2024
Free Cash Flow (TTM)
−$92.04M
Q1 Apr 2024
Cash
$27.79M
Q1 Apr 2024
Total Debt
$99.69M
Q1 Apr 2024
Shares Outstanding
85.06M sh
Q1 Apr 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings